Catalent (CTLT) – Investment Analysts’ Recent Ratings Changes


Share on StockTwits

A number of research firms have changed their ratings and price targets for Catalent (NYSE: CTLT):

  • 2/11/2021 – Catalent was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
  • 2/8/2021 – Catalent was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $127.00 price target on the stock. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
  • 2/3/2021 – Catalent had its price target raised by analysts at Morgan Stanley from $115.00 to $135.00. They now have an “overweight” rating on the stock.
  • 2/3/2021 – Catalent had its price target raised by analysts at Royal Bank of Canada from $125.00 to $137.00. They now have an “outperform” rating on the stock.
  • 2/3/2021 – Catalent had its price target raised by analysts at UBS Group AG from $115.00 to $135.00. They now have a “buy” rating on the stock.
  • 1/29/2021 – Catalent was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
  • 1/28/2021 – Catalent was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $123.00 price target on the stock. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
  • 1/20/2021 – Catalent was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $134.00 price target on the stock. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
  • 1/19/2021 – Catalent was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
  • 1/13/2021 – Catalent was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
  • 1/12/2021 – Catalent was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $129.00 price target on the stock. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
  • 1/8/2021 – Catalent had its price target raised by analysts at JPMorgan Chase & Co. from $110.00 to $130.00. They now have an “overweight” rating on the stock.
  • 1/7/2021 – Catalent was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “

CTLT traded down $2.61 on Tuesday, hitting $111.71. The company had a trading volume of 29,936 shares, compared to its average volume of 987,315. The company has a market cap of $19.02 billion, a PE ratio of 71.15, a PEG ratio of 2.68 and a beta of 1.50. Catalent, Inc. has a 12-month low of $31.04 and a 12-month high of $127.68. The company has a quick ratio of 2.14, a current ratio of 2.56 and a debt-to-equity ratio of 0.97. The business’s fifty day simple moving average is $115.92 and its 200 day simple moving average is $98.82.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Monday, February 1st. The company reported $0.63 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.08. The business had revenue of $910.80 million during the quarter, compared to the consensus estimate of $893.68 million. Catalent had a net margin of 9.25% and a return on equity of 14.20%. The firm’s quarterly revenue was up 26.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.45 earnings per share. On average, analysts anticipate that Catalent, Inc. will post 2.35 earnings per share for the current fiscal year.

In other news, insider Ricci S. Whitlow sold 692 shares of Catalent stock in a transaction that occurred on Thursday, January 21st. The shares were sold at an average price of $118.85, for a total transaction of $82,244.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Aristippos Gennadios sold 13,662 shares of Catalent stock in a transaction that occurred on Monday, December 21st. The shares were sold at an average price of $102.84, for a total transaction of $1,405,000.08. The disclosure for this sale can be found here. In the last three months, insiders sold 27,034 shares of company stock valued at $2,974,324. 1.00% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CTLT. First Horizon Advisors Inc. boosted its position in Catalent by 16.2% in the fourth quarter. First Horizon Advisors Inc. now owns 646 shares of the company’s stock valued at $67,000 after buying an additional 90 shares during the last quarter. Signaturefd LLC increased its stake in shares of Catalent by 34.1% in the fourth quarter. Signaturefd LLC now owns 558 shares of the company’s stock worth $58,000 after acquiring an additional 142 shares during the period. Profund Advisors LLC increased its stake in shares of Catalent by 1.1% in the fourth quarter. Profund Advisors LLC now owns 12,979 shares of the company’s stock worth $1,351,000 after acquiring an additional 144 shares during the period. CENTRAL TRUST Co increased its stake in shares of Catalent by 10.9% in the fourth quarter. CENTRAL TRUST Co now owns 1,592 shares of the company’s stock worth $166,000 after acquiring an additional 157 shares during the period. Finally, Park Avenue Securities LLC increased its stake in shares of Catalent by 4.0% in the third quarter. Park Avenue Securities LLC now owns 4,322 shares of the company’s stock worth $370,000 after acquiring an additional 168 shares during the period. 97.84% of the stock is currently owned by institutional investors and hedge funds.

Catalent, Inc, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.

Featured Story: What is basic economics?

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.